S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
NASDAQ:CHRS

Coherus BioSciences Stock Forecast, Price & News

$17.73
+0.21 (+1.20 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.30
$17.89
50-Day Range
$12.68
$17.56
52-Week Range
$12.21
$22.22
Volume426,986 shs
Average Volume970,655 shs
Market Capitalization$1.36 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02
30 days | 90 days | 365 days | Advanced Chart
Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.


Coherus BioSciences logo

About Coherus BioSciences

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.90 out of 5 stars

Medical Sector

669th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

105th out of 193 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Coherus BioSciences (NASDAQ:CHRS) Frequently Asked Questions

Is Coherus BioSciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Coherus BioSciences stock.
View analyst ratings for Coherus BioSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Coherus BioSciences?

Wall Street analysts have given Coherus BioSciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Coherus BioSciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Coherus BioSciences' next earnings date?

Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Coherus BioSciences
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) issued its earnings results on Thursday, August, 5th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.15. The biotechnology company had revenue of $87.64 million for the quarter, compared to analysts' expectations of $82.65 million. Coherus BioSciences had a negative net margin of 41.86% and a negative trailing twelve-month return on equity of 80.53%.
View Coherus BioSciences' earnings history
.

How has Coherus BioSciences' stock price been impacted by COVID-19?

Coherus BioSciences' stock was trading at $15.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CHRS stock has increased by 11.7% and is now trading at $17.73.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CHRS?

4 brokerages have issued 1 year price objectives for Coherus BioSciences' shares. Their forecasts range from $22.00 to $36.00. On average, they expect Coherus BioSciences' stock price to reach $27.80 in the next year. This suggests a possible upside of 56.8% from the stock's current price.
View analysts' price targets for Coherus BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Coherus BioSciences' key executives?

Coherus BioSciences' management team includes the following people:

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.87%), State Street Corp (6.63%), Alliancebernstein L.P. (5.95%), Vanguard Group Inc. (5.85%), Aristotle Capital Boston LLC (2.60%) and Geode Capital Management LLC (1.55%). Company insiders that own Coherus BioSciences stock include Dennis M Lanfear, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends for Coherus BioSciences
.

Which institutional investors are selling Coherus BioSciences stock?

CHRS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Aristotle Capital Boston LLC, AQR Capital Management LLC, Prudential Financial Inc., Rice Hall James & Associates LLC, Morgan Stanley, Morgan Stanley, and First Trust Advisors LP. Company insiders that have sold Coherus BioSciences company stock in the last year include Dennis M Lanfear, Jean-Frederic Viret, Vincent R Anicetti, and Vladimir Vexler.
View insider buying and selling activity for Coherus BioSciences
or view top insider-selling stocks.

Which institutional investors are buying Coherus BioSciences stock?

CHRS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Alliancebernstein L.P., Bank of Montreal Can, State Street Corp, Jefferies Group LLC, Jefferies Group LLC, Vanguard Group Inc., and Peregrine Capital Management LLC.
View insider buying and selling activity for Coherus BioSciences
or or view top insider-buying stocks.

How do I buy shares of Coherus BioSciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $17.73.

How much money does Coherus BioSciences make?

Coherus BioSciences has a market capitalization of $1.36 billion and generates $475.82 million in revenue each year. The biotechnology company earns $132.24 million in net income (profit) each year or $1.62 on an earnings per share basis.

How many employees does Coherus BioSciences have?

Coherus BioSciences employs 317 workers across the globe.

Does Coherus BioSciences have any subsidiaries?

The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..

When was Coherus BioSciences founded?

Coherus BioSciences was founded in 2010.

What is Coherus BioSciences' official website?

The official website for Coherus BioSciences is www.coherus.com.

Where are Coherus BioSciences' headquarters?

Coherus BioSciences is headquartered at 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065.

How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at (650) 649-3530 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.